SXTP (60 Degrees Pharmaceuticals) Risk Assessment


SXTP 60 Degrees Pharmaceuticals Inc SXTP
44 GF Score
Price $1.55
GF Value $2.03
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is 60 Degrees Pharmaceuticals Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of 60 Degrees Pharmaceuticals is: High Risk: High uncertainty with risk-return tradeoff.

60 Degrees Pharmaceuticals  (NAS:SXTP) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

60 Degrees Pharmaceuticals Risk Assessment Related Terms

SXTP vs GLMD, FBLG, CELZ: Risk Assessment Comparison

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

60 Degrees Pharmaceuticals Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's Risk Assessment distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's Risk Assessment falls into.


SXTP
44GF Score
60 Degrees Pharmaceuticals Inc SXTP
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is 60 Degrees Pharmaceuticals (SXTP) Overvalued in 2026?

Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals stock appears to be undervalued. The current stock price of $1.55 is trading 23.6% below its estimated GF Value™ of $2.03. GuruFocus considers 60 Degrees Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for SXTP:

  • Risk Assessment:
  • GF Value™: $2.03 vs. price of $1.55 (23.6% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the SXTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

60 Degrees Pharmaceuticals Business Description

Address 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
44GF Score

Get the complete analysis for SXTP

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price
$2.03
GF Value